

AMENDMENTS TO THE CLAIMS

1-9. (canceled).

10. (previously presented) A controlled release microparticle composition comprising a bioactive agent in a polymer produced through a process which comprises the steps of:

a) combining a biodegradable polymer and an organic phase;

b) combining a bioactive agent and said organic phase;

c) combining an organic ion and an aqueous phase; wherein the organic ion is selected from trifluoromethyl-p-toluate, 2-naphthalene sulfonate, 2,3-naphthalene dicarboxylate, 1-hydroxy-2-naphthoate, 3-hydroxy-2-naphthoate, 2-naphthoate, and salicylsalicylate;

d) contacting the organic and aqueous phases through the use of an emulsion process; and

e) recovering said microparticles to produce a controlled release composition.

11. (original) The composition of claim 10, wherein said composition is selected from the group consisting of microparticles and nanoparticles.

12. (original) The composition of claim 11, wherein said microparticles and nanoparticles are biodegradable.

13. (original) The composition of claim 10, wherein said polymer is selected from the group consisting of poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polycaprolactone, polycarbonates, polyesteramides, polyanhydrides, poly(amino acids), polyorthoesters, polyacetyls, polycyanoacrylates, polyetheresters, poly(dioxanone)s, poly(alkylene

alkylate)s, copolymers of polyethylene glycol and polyorthoester, biodegradable polyurethanes, blends and copolymers thereof.

14. (original) The composition of claim 10, wherein said bioactive agent is selected from the group consisting of proteins, nucleic acids, carbohydrates, peptides, LHRH agonists and synthetic analogs thereof, leuprolide, oxytocin, somatostatin and synthetic analogs thereof, small molecule pharmaceutical substances, immunogens, metabolic precursors capable of promoting growth and survival of cells and tissues, antineoplastic agents, hormones, antihistamines, cardiovascular agents, anti-ulcer agents, bronchodilators, vasodilators, central nervous system agents and narcotic antagonists.

15. (canceled).

16. (original) The composition of claim 10, wherein the stoichiometry of the bioactive agent relative to the organic ion ranges from about 1.0 to 1.5.

17. (currently amended) The composition of claim 10, wherein the bioactive agent is selected from the group consisting of octreotide[[,]] and octreotide acetate ~~and the organic ion is pamoate.~~

18. (original) The composition of claim 10, wherein the organic ion interacts with the bioactive agent to form a charged or neutral complex.

19-36. (canceled).

37. (new) The composition of claim 10, wherein the organic ion is selected from trifluoromethyl-p-toluate, 2,3-naphthalene dicarboxylate, 1-hydroxy-2-naphthoate, 3-hydroxy-2-naphthoate, 2-naphthoate, and salicylsalicylate.